List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Overview
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Companies Involved in Therapeutics Development
Asterias Biotherapeutics Inc
e-Therapeutics Plc
F. Hoffmann-La Roche Ltd
GemVax & KAEL Co Ltd
Geron Corp
Inovio Pharmaceuticals Inc
Invectys SA
Komipharm Intertiol Co Ltd
Mediolanum farmaceutici SpA
Takis Srl
Telocyte LLC
TILT Biotherapeutics Ltd
Ultimovacs AS
Vaxon Biotech
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Drug Profiles
Antisense Gene Therapy to Inhibit Telomerase Reverse Transcriptase for Ovarian Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASTVAC-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ETS-2300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Telomerase for Aplastic Anemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate TERT for Alzheimer’s Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GX-301 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
imetelstat sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-1400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INO-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INVAC-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KML-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ribovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Activate Telomerase for Men Infertility and Women Infertility - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Telomerase for Lung Cancer and Melanoma - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit TERT for Prostate Cancer - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Telomerase for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEL-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
telin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tertomotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TILT-234 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TK-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UCPVax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
UV-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-016 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vbx-026 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vx-006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Dormant Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Discontinued Products
Telomerase Reverse Transcriptase (HEST2 or Telomerase Catalytic Subunit or Telomerase Associated Protein 2 or TERT or EC 2.7.7.49) - Product Development Milestones
Featured News & Press Releases
Sep 04, 2018: Asterias Biotherapeutics announces positive outcome from Second Safety Review Committee Meeting and open enrollment for VAC2 clinical trial in non-small cell lung cancer (NSCLC)
Aug 20, 2018: Inovio doses first patient in Phase l/lla of INO-5401 and atezolizumab
Jul 11, 2018: Asterias Biotherapeutics Announces Positive Outcome from Safety Review Committee for AST-VAC2; Recommends Continuation of Clinical Trial in Non-Small Cell Lung Cancer (NSCLC)
Jun 28, 2018: Southampton vaccite first patient to phase 1 study
Jun 21, 2018: Inovio Announces Treatment of First Patient in Immuno-Oncology Study for Glioblastoma (GBM) with INO-5401 in Combition with Regeneron’s PD-1 Inhibitor
Jun 18, 2018: Geron Reports Imetelstat Oral Presentation at European Hematology Association Congress
Jun 12, 2018: Cancer Research Uk Tests First Of Its Kind Vaccine To Treat Lung Cancer
May 17, 2018: Geron Announces Oral Presentation at European Hematology Association Congress
May 16, 2018: Asterias Biotherapeutics to Discuss Cancer Immunotherapy Product AST-VAC2 at the World Advanced Therapies and Regenerative Medicine Congress
Apr 25, 2018: Asterias Announces Clinical Grade Lot Released to Support Dosing of First Subjects in First Clinical Study of AST-VAC2
Apr 16, 2018: GemVax & KAEL Announces Positive Phase 2 Data on GV1001 for Prostate Hyperplasia
Mar 24, 2018: New Preclinical Data for THIO in BRAF-Mutant Mouse Melanoma Models
Jan 30, 2018: CNIO researchers cure lung fibrosis in mice with a gene therapy that lengthens telomeres
Jan 04, 2018: Asterias Biotherapeutics Provides Update on ASTVAC-2
Dec 19, 2017: PharmaJet and Invectys Partner in Phase II Clinical Trial of D Cancer Vaccine
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer